Innate Pharma (IPH) investor relations material

Strategic focus and portfolio

• Concentrates on three high-value clinical assets: lacutamab, IPH4502, and monalizumab, each targeting significant unmet needs in oncology.

• Organization is structured for agile execution and value creation, leveraging in-house antibody expertise.

Lacutamab: Clinical and commercial potential

• Lacutamab, an anti-KIR3DL2 antibody, targets CTCL and PTCL, showing durable activity and favorable tolerability in Phase 2 trials.

• Demonstrated strong clinical benefit in Sézary syndrome and mycosis fungoides, with high response rates and improved quality of life.

• Received Breakthrough Therapy and Fast Track designations, with a path to accelerated approval in SS; Phase 3 initiation planned for H2 2026, pending financing.

• Market potential in CTCL estimated at over $500 million, with opportunity to expand use in early-stage and other CTCL patients.

IPH4502: Next-generation ADC

• IPH4502 is a differentiated Nectin-4 exatecan ADC, showing preliminary anti-tumor activity in heavily pre-treated solid tumor patients, including post-EV urothelial cancer.

• Phase 1 dose escalation completed, with favorable safety profile and limited hematological toxicity.

• Designed to address treatment gaps in post-EV settings and unlock activity in low-expressing tumors.